An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis

Acne keloidalis (AK) is a disease affecting primarily African American men. Topical steroids are a widely accepted treatment of AK; however, no studies have been published investigating their effectiveness. The purpose of this open-label study was to assess the efficacy and tolerability of clobetaso...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cutis (New York, N.Y.) N.Y.), 2005-06, Vol.75 (6), p.317
Hauptverfasser:	Callender, Valerie D, Young, Cherie M, Haverstock, Christina L, Carroll, Christie L, Feldman, Steven R
Format:	Artikel
Sprache:	eng
Schlagworte:	Acne Keloid - drug therapy Administration, Topical Adult African Americans Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - adverse effects Betamethasone Valerate - administration & dosage Betamethasone Valerate - adverse effects Clobetasol - administration & dosage Clobetasol - adverse effects Clobetasol - analogs & derivatives Female Humans Male Middle Aged Quality of Life Scalp Dermatoses - drug therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Acne keloidalis (AK) is a disease affecting primarily African American men. Topical steroids are a widely accepted treatment of AK; however, no studies have been published investigating their effectiveness. The purpose of this open-label study was to assess the efficacy and tolerability of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of AK in 20 African American patients. These patients were treated for 8 to 12 weeks using a pulsed-dose regimen. We found topical clobetasol propionate foam to be effective in improving AK, and our patients found the foam vehicle to be cosmetically acceptable.
ISSN:	0011-4162